# US 2020/0138912 A1 · Superior control of blood glucose in diabetes treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138912 A1
- Document ID: US20200138912A1
- Status: Published application
- Kind: A1
- Application number: 16/736,692
- Filed: 2020-01-07
- Published: 2020-05-07
- Earliest claimed: 2005-03-31
- Assignees: MannKind Corporation
- Applicants: MannKind Corporation
- Inventors: Wayman Wendell Cheatham; Anders Hasager Boss
- Web page: https://patentgrep.com/patent/US20200138912A1

## CPC

- A61K 38/28: Insulins
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.

## Claims

### Claim 1

A method of reducing postprandial glucose excursions in a patient with an insulin-related disorder comprising:
selecting a patient with an insulin-related disorder;
administering a dose of an insulin composition comprising fumaryl diketopiperazine in a form suitable for pulmonary administration in proximity to beginning a meal, wherein the patient's total insulin exposure (INS-AUC0-y, 3≤y≤6 hours) from said dose does not substantially exceed that produced by an appropriate subcutaneous dose of insulin; and
reducing the postprandial glucose excursions relative to treatment with the appropriate subcutaneous dose of insulin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the risk of late postprandial hypoglycemia is not increased.

### Claim 3 (depends on 1)

The method of claim 1, wherein the insulin composition is administered by inhalation as a dry powder.

### Claim 4 (depends on 1)

The method of claim 1, wherein the insulin composition is administered from approximately 10 minutes prior to beginning a meal to approximately 30 minutes after beginning a meal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the insulin-related disorder is diabetes mellitus.

### Claim 6 (depends on 1)

The method of claim 1, wherein a mean glucose excursion is at least about 25% less than for said appropriate subcutaneous dose of insulin.

### Claim 7 (depends on 1)

The method of claim 1, wherein glucose excursions are measured by a method selected from the group consisting of AUC0-240, AUC0-120, and maximum glucose excursion.

### Claim 8 (depends on 7)

The method of claim 7, wherein the maximum glucose excursion does not exceed a blood glucose concentration of 180 mg/dL.

### Claim 9 (depends on 7)

The method of claim 7, wherein the maximum glucose excursion does not exceed a premeal baseline blood glucose concentration by a value of more than 59 mg/dL.

### Claim 10 (depends on 1)

The method according to claim 1 wherein as a result of said administering step, said patient exhibits a ratio of HbA1c after treatment to HbA1c before treatment less than for subcutaneous administration of a dose of insulin providing substantially similar insulin exposure.

### Claim 11

A method of treating a patient with an insulin related disorder comprising:
administering an insulin composition comprising a diketopiperazine and insulin in a form suitable for pulmonary administration from between from 10 minutes prior to beginning a meal to 30 minutes after beginning a meal;
wherein said composition induces a maximum glucose elimination rate in said patient within 60 minutes of administration.

### Claim 12 (depends on 11)

The method according to claim 11 wherein said glucose elimination rate falls to half-maximal within 80 minutes of reaching the maximum.

### Claim 13 (depends on 11)

The method according to claim 11 wherein said diketopiperazine is fumaryl diketopiperazine.

### Claim 14 (depends on 11)

The method according to claim 11 wherein said insulin-related disorder is diabetes mellitus.

### Claim 15 (depends on 11)

The method according to claim 11 wherein the risk of late postprandial hypoglycemia is not increased.

### Claim 16 (depends on 11)

The method according to claim 11 wherein as a result of said administering step, said patient exhibits a ratio of HbA1c after treatment to HbA1c before treatment less than for subcutaneous administration of a dose of insulin providing substantially similar insulin exposure.

### Claim 17

A method of treating a patient with an insulin related disorder comprising:
administering an insulin composition comprising a diketopiperazine and insulin in a form suitable for pulmonary administration from between 10 minutes prior to beginning a meal to 30 minutes after beginning a meal;
wherein said composition induces a lower coefficient of variation at the 95% confidence interval of insulin exposure, (INS-AUC0-x, x≤3 hours) or glucose elimination ((GIR-)AUC0-x, x≤3 hours), in said patient than subcutaneously administered insulin, where the total insulin exposure [INS-AUC0-y, 3≤y≤6] is substantially similar.

### Claim 18 (depends on 17)

The method according to claim 17 wherein said diketopiperazine is fumaryl diketopiperazine.

### Claim 19 (depends on 17)

The method according to claim 17 wherein said insulin-related disorder is diabetes mellitus.

### Claim 20 (depends on 17)

The method according to claim 17 wherein the risk of late postprandial hypoglycemia is not increased.
